{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:09:29Z","timestamp":1789556969500,"version":"build-2803163510"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>With 5\u2009years of follow-up in the phase 3 CROWN study, lorlatinib showed unprecedented improvement in progression-free survival coupled with prolonged intracranial efficacy in patients with ALK-positive metastatic non-small cell lung cancer (mNSCLC). Here, we report kinetics and mitigation practices of select adverse events (AEs) to inform therapy management strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Post hoc safety analyses from the CROWN study assessed the incidence, prevalence, time to onset, duration, management, and resolution of hyperlipidemia, edema, weight gain, central nervous system (CNS) AEs, and peripheral neuropathy in the lorlatinib group (n\u2009=\u2009149).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 5\u2009years of follow-up, no new safety signals were observed. All-cause any-grade and grade 3\/4 AEs occurred in 100% and 77% of patients, respectively; AEs led to lorlatinib dose reduction in 23% of patients, dose interruption in 62%, and permanent discontinuation in 11%. The median time to onset of any-grade hyperlipidemia was 0.5\u2009months; 71% of events were managed with lipid-lowering agents. Median time to onset of any-grade edema, weight gain, CNS AEs, and peripheral neuropathy ranged from 2 to 4\u2009months. Most weight gain events (95%) were mitigated with lifestyle modifications. Incidence and prevalence of CNS AEs did not increase over time; 58% of events did not require medical intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This post hoc analysis suggests that with longer lorlatinib exposure, no new safety signals emerged, and treatment discontinuation due to AEs remained low after 5\u2009years of follow-up. Most AEs were effectively managed with dose modifications, indicating that current management strategies can be effective to mitigate toxicity. ClinicalTrials.gov NCT03052608<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf287","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T11:48:51Z","timestamp":1760788131000},"source":"Crossref","is-referenced-by-count":9,"title":["Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2603-7296","authenticated-orcid":false,"given":"Geoffrey","family":"Liu","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, University of Toronto , Toronto, ON M5G 2M9,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J","family":"Solomon","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, University of Melbourne , Melbourne, VIC 3000,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[{"name":"Toulouse University Hospital and Centre de Recherche Canc\u00e9rologie Toulouse CRCT, INSERM, Toulouse University , Toulouse 31100,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[{"name":"College of Medicine and Seoul National University Hospital, Seoul National University , Seoul 03080,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cortinovis","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS San Gerardo dei Tintori Monza, University of Milano-Bicocca , Milano 20900,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Inoue","sequence":"additional","affiliation":[{"name":"Osaka International Cancer Institute , Osaka 540-0008,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richu","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Artemis Hospital , Gurugram, Haryana 12201,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Thurm","sequence":"additional","affiliation":[{"name":"Global Product Development, Clinical Pharmacology, Pfizer , San Diego, CA 92121,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polli","sequence":"additional","affiliation":[{"name":"Oncology Statistics, Pfizer , Milan 20152,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M","family":"Bauer","sequence":"additional","affiliation":[{"name":"Greco-Hainsworth Centers for Research, Tennessee Oncology , Nashville, TN 37203,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"2025102708072999700_oyaf287-B1","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"2025102708072999700_oyaf287-B2","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","article-title":"Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations","volume":"57","author":"Johnson","year":"2014","journal-title":"J Med Chem"},{"key":"2025102708072999700_oyaf287-B3","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"2025102708072999700_oyaf287-B4","author":"Pfizer","year":"2023"},{"key":"2025102708072999700_oyaf287-B5","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025102708072999700_oyaf287-B6","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"2025102708072999700_oyaf287-B7","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025102708072999700_oyaf287-B8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025102708072999700_oyaf287-B9","doi-asserted-by":"crossref","first-page":"107535","DOI":"10.1016\/j.lungcan.2024.107535","article-title":"A pragmatic guide for management of adverse events associated with lorlatinib","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"key":"2025102708072999700_oyaf287-B10","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1007\/s12325-020-01365-3","article-title":"Consensus recommendations for management and counseling of adverse events associated with lorlatinib: a guide for healthcare practitioners","volume":"37","author":"Reed","year":"2020","journal-title":"Adv Ther"},{"key":"2025102708072999700_oyaf287-B11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2018-0380","article-title":"Clinical management of adverse events associated with lorlatinib","volume":"24","author":"Bauer","year":"2019","journal-title":"Oncologist"},{"key":"2025102708072999700_oyaf287-B12","doi-asserted-by":"crossref","first-page":"102969","DOI":"10.1016\/j.critrevonc.2020.102969","article-title":"A user\u2019s guide to lorlatinib","volume":"151","author":"Nagasaka","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025102708072999700_oyaf287-B13","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s12325-022-02050-3","article-title":"Podcast on the management of adverse events associated with lorlatinib","volume":"39","author":"Bauer","year":"2022","journal-title":"Adv Ther"},{"key":"2025102708072999700_oyaf287-B14","doi-asserted-by":"crossref","first-page":"101560","DOI":"10.1016\/j.esmoop.2023.101560","article-title":"Expert consensus of management of adverse drug reactions with anaplastic lymphoma kinase tyrosine kinase inhibitors","volume":"8","author":"Zhou","year":"2023","journal-title":"ESMO Open"},{"key":"2025102708072999700_oyaf287-B15","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/OTT.S426989","article-title":"Recent advances in the management of adverse events associated with lorlatinib","volume":"16","author":"Liao","year":"2023","journal-title":"Onco Targets Ther"},{"key":"2025102708072999700_oyaf287-B16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40261-024-01379-7","article-title":"Expert consensus on the management of adverse events of lorlatinib in the treatment of ALK+ advanced non-small cell lung cancer","volume":"44","author":"Arriola","year":"2024","journal-title":"Clin Drug Investig"},{"key":"2025102708072999700_oyaf287-B17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1007\/s40262-021-01015-z","article-title":"Pharmacokinetics of lorlatinib after single and multiple dosing in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer: results from a global phase I\/II study","volume":"60","author":"Chen","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2025102708072999700_oyaf287-B18","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1002\/jcph.1621","article-title":"Metabolism, excretion, and pharmacokinetics of lorlatinib (PF-06463922) and evaluation of the impact of radiolabel position and other factors on comparability of data across 2 ADME studies","volume":"60","author":"Stypinski","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2025102708072999700_oyaf287-B19","first-page":"100546","article-title":"Lorlatinib tolerability and association with clinical outcomes in patients with advanced ALK- or ROS1-rearranged NSCLC: a brief report","volume":"4","author":"Thummalapalli","year":"2023","journal-title":"JTO Clin Res Rep"},{"key":"2025102708072999700_oyaf287-B20","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025102708072999700_oyaf287-B21","doi-asserted-by":"crossref","first-page":"107954","DOI":"10.1016\/j.lungcan.2024.107954","article-title":"Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification","volume":"196","author":"Igawa","year":"2024","journal-title":"Lung Cancer"},{"key":"2025102708072999700_oyaf287-B22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/curroncol28010029","article-title":"Evaluation and management of dyslipidemia in patients treated with lorlatinib","volume":"28","author":"Blais","year":"2021","journal-title":"Curr Oncol"},{"key":"2025102708072999700_oyaf287-B23","doi-asserted-by":"crossref","first-page":"e176","DOI":"10.1016\/j.cllc.2023.03.016","article-title":"The efficacy of PCSK9 inhibitors in treating hypercholesterolemia caused by lorlatinib: a report of two cases","volume":"24","author":"Khairunnisa","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2025102708072999700_oyaf287-B24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"2025102708072999700_oyaf287-B25","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jtho.2023.03.020","article-title":"Analysis of serious weight gain in patients using alectinib for ALK-positive lung cancer","volume":"18","author":"de Leeuw","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2025102708072999700_oyaf287-B26","doi-asserted-by":"crossref","first-page":"S817","DOI":"10.1016\/j.annonc.2024.08.1337","article-title":"Effects of semaglutide on the exposure of alectinib in patients with NSCLC","volume":"35","author":"Lanser","year":"2024","journal-title":"Ann Oncol."},{"key":"2025102708072999700_oyaf287-B27","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1002\/cam4.3061","article-title":"The underlying mechanisms of lorlatinib penetration across the blood-brain barrier and the distribution characteristics of lorlatinib in the brain","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med"},{"key":"2025102708072999700_oyaf287-B28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jtho.2022.09.219","article-title":"Factors associated with developing neurocognitive adverse events in patients receiving lorlatinib after progression on other targeted therapies","volume":"18","author":"Dagogo-Jack","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2025102708072999700_oyaf287-B29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.cllc.2023.12.003","article-title":"In-depth analysis of lorlatinib-related neurocognitive adverse events in patients with non-small-cell lung cancer","volume":"25","author":"Schoenmaekers","year":"2024","journal-title":"Clin Lung Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf287\/64855807\/oyaf287.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf287\/64855807\/oyaf287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf287\/64855807\/oyaf287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:07:39Z","timestamp":1761566859000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf287\/8296870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf287","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10,1]]},"article-number":"oyaf287"}}